Cell Biotech Co

Cell Biotech Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 104.64. In the previous year, Cash Conversion Cycle (CCC) was 126.20 — a change of -17.08% (lower).

Cash Conversion Cycle

104.64

YoY

-17.08%

Last updated:

Cash Conversion Cycle (CCC) of Cell Biotech Co is 2025 104.64 . Cash Conversion Cycle (CCC) of Cell Biotech Co was 2024 126.20 . It decreases by -17.08% lower compared to the previous year.

The Cell Biotech Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
85.05 KRW
Jan 1, 2019
109.46 KRW
Jan 1, 2020
127.17 KRW
Jan 1, 2021
114.07 KRW
Jan 1, 2022
115.16 KRW
Jan 1, 2023
123.79 KRW
Jan 1, 2024
126.20 KRW
Jan 1, 2025
104.64 KRW
The Cell Biotech Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
104.64-17.08%
126.20+1.95%
123.79+7.49%
115.16+0.95%
114.07-10.29%
127.17+16.18%
109.46+28.69%
85.05-6.42%
90.89+0.78%
90.18-10.60%
100.88-4.28%
105.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Cash Conversion Cycle (CCC) of Cell Biotech Co is 104.64 in 2025.

Cash Conversion Cycle (CCC) of Cell Biotech Co changed from 126.20 to 104.64, representing a -17.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cell Biotech Co

All Key Metrics — Cell Biotech Co